- Home
- RCUS vs EOI Comparison
RCUS vs EOI Comparison
Compare RCUS & EOI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCUS
- EOI
- Stock Information
- Founded
- RCUS 2015
- EOI 2004
- Country
- RCUS United States
- EOI United States
- Employees
- RCUS N/A
- EOI N/A
- Industry
- RCUS Biotechnology: Pharmaceutical Preparations
- EOI Finance/Investors Services
- Sector
- RCUS Health Care
- EOI Finance
- Exchange
- RCUS Nasdaq
- EOI Nasdaq
- Market Cap
- RCUS 727.1M
- EOI 827.9M
- IPO Year
- RCUS 2018
- EOI N/A
- Fundamental
- Price
- RCUS $7.88
- EOI $17.40
- Analyst Decision
- RCUS Strong Buy
- EOI
- Analyst Count
- RCUS 10
- EOI 0
- Target Price
- RCUS $29.50
- EOI N/A
- AVG Volume (30 Days)
- RCUS 1.2M
- EOI 83.6K
- Earning Date
- RCUS 05-07-2025
- EOI 01-01-0001
- Dividend Yield
- RCUS N/A
- EOI 7.19%
- EPS Growth
- RCUS N/A
- EOI N/A
- EPS
- RCUS N/A
- EOI N/A
- Revenue
- RCUS $258,000,000.00
- EOI N/A
- Revenue This Year
- RCUS N/A
- EOI N/A
- Revenue Next Year
- RCUS $25.77
- EOI N/A
- P/E Ratio
- RCUS N/A
- EOI N/A
- Revenue Growth
- RCUS 120.51
- EOI N/A
- 52 Week Low
- RCUS $6.50
- EOI $14.36
- 52 Week High
- RCUS $18.98
- EOI $18.88
- Technical
- Relative Strength Index (RSI)
- RCUS 44.26
- EOI 38.61
- Support Level
- RCUS $6.75
- EOI $17.24
- Resistance Level
- RCUS $8.36
- EOI $18.38
- Average True Range (ATR)
- RCUS 0.60
- EOI 0.75
- MACD
- RCUS 0.16
- EOI 0.01
- Stochastic Oscillator
- RCUS 74.19
- EOI 54.44
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
About EOI Eaton Vance Enhance Equity Income Fund Eaton Vance Enhanced Equity Income Fund Shares of Beneficial Interest
Eaton Vance Enhanced Equity Income Fund offers mutual funds that invest across a wide array of equity, income and alternative strategies. The primary investment objective of the fund is to provide current income, with a secondary objective of capital appreciation.